Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness and safety of TLK286 given
intravenously once every week in the treatment of patients with advanced ovarian cancer that
is resistant to platinum-based chemotherapy.